Tag: Cuvitru

Shire bags US nod for primary immunodeficiency drug

by Selina McKee | Sep 15, 2016 | News | 0

Shire’s immunology portfolio has been given a boost with US approval for Cuvitru for the treatment of primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing or failing.

Shire completes EU decentralisation procedure for Cuvitru

by Selina McKee | Jun 13, 2016 | News | 0

Shire’s Cuvitru is a big step closer to a roll-out in Europe having completed the decentralised procedure supporting its approval for primary and certain secondary immunodeficiency disorders.